Prolonged action and low daily variability in the regulatory effect of glucose provide potential for swallow , an injectable insulin in the last test phase, can be used three times byWeek, as presented at the EASD meeting.
From a daily injectable dose to three injections a week: this is the contribution of the swallowing drug to the developing therapeutic arsenal for diabetes.Prepared by the Pharmaceutical Company Novo Nordisk and presented at the XLVI Annual Meeting of the European Association for the Study of Diabetes, held in Stockholm, the medicine is a basal insulin that forms multi -metemers soluble by subcutaneous injection, giving rise to the formation of aDeposit from which this insulin is absorbed continuously and slowly to circulation.Thus, your action profile is slow and prolonged.
Chantal Mathieu, Professor of Medicine at the Catholic University of Leuven, in Belgium, explained that the test studies in phase II carried out to assess the efficacy and safety of Degludec used daily or three times per week show that this insulin is finetolerated and that improves glycemic control in people with type 2 diabetes who have not been previously treated with insulin."After 16 weeks of treatment with swallowing, glycosylated hemoglobin reductions (HBA1C) are similar in groups that are treated daily or three times per week (-1.3 percent and -1.5 percent, respectively) andSimilar with glargine (-1.5 percent) ".
Difficult to forget
Regarding the question of whether patients run the risk of forgetting any insulin doses by not having to administer it daily, Mathieu has commented that "it is difficult for them to forget this advantage."
According to Mads Krogsgaard Thomsen, executive vice president of Novo Nordisk, in Copenhagen (Denmark), "its prolonged action and low daily variability in the regulatory effect of glucose provide potential for Degludec to be used three times per week making it easier to meet theInsulin treatment.In fact, Novo Nordisk is currently carrying out a phase III research program, called Begin, to study the clinical profile of Degludec.7,000 patients from twelve essays participate in this
Another important characteristic of Degludec is, in the opinion of Rafael Simó, head of the Endocrinology Section of the Hebron Valle Hospital, in Barcelona, which reduces the number of possible hypoglycemia."A study comparing Degludec with insulin Glargina points out that hypoglycemia are lower with the first (77 percent compared to 92 percent)."
According to Krogsgaard, "this is key because with other treatments the benefits of good glycemic control are usually affected by a greater number of hypoglycemia."
on liraglutida
On the other hand, at the Stockholm meeting, Melanie Davies, a diabetes professor at Leicester University Hospital, in the United Kingdom, has shown that "it is an extended perception among diabetes specialists that patients prefer oral therapies to oral therapies toInjectables to reduce their glucose.The reason may be that liraglutida offers a higher clinical profile and greater satisfaction with the treatment.
Diabetes of the family environment
In Spain, 8.7 percent of the population is diabetic.As Teresa Briones, Medical Advisor atNovo Nordisk diabetes, as a medical daily, this pathology also significantly affects the family environment of patients."There are even studies that say that when a type 1 diabetic debuts in a family, their mother stops working. That is why safe treatments that provide peace of minds to those surrounding the diabetic in case they suffer hypoglycemia."For Simó, which currently directs the Research Group in Diabetes and Metabolism of the Research Institute of the aforementioned Center, the diabetes problem is of great magnitude;If not, "why have 10,000 health specialists gathered in Stockholm to discuss a single pathology? In the world population Diabetes is the main cause of blindness, chronic renal failure and amputations of lower limbs that are not produced by accident".
